| Literature DB >> 24278487 |
Didier Menard1, Ernest R Chan, Christophe Benedet, Arsène Ratsimbasoa, Saorin Kim, Pheaktra Chim, Catherine Do, Benoit Witkowski, Remy Durand, Marc Thellier, Carlo Severini, Eric Legrand, Lise Musset, Bakri Y M Nour, Odile Mercereau-Puijalon, David Serre, Peter A Zimmerman.
Abstract
BACKGROUND: Plasmodium vivax is the most prevalent human malaria parasite, causing serious public health problems in malaria-endemic countries. Until recently the Duffy-negative blood group phenotype was considered to confer resistance to vivax malaria for most African ethnicities. We and others have reported that P. vivax strains in African countries from Madagascar to Mauritania display capacity to cause clinical vivax malaria in Duffy-negative people. New insights must now explain Duffy-independent P. vivax invasion of human erythrocytes. METHODS/PRINCIPALEntities:
Mesh:
Substances:
Year: 2013 PMID: 24278487 PMCID: PMC3836732 DOI: 10.1371/journal.pntd.0002489
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Summary of all DNA sequence rearrangements identified.
| Chromo-some | Start | End | Length | Type | Sal I | Belem | C08 | C127 | C15 | M08 | M15 | M19 | Brazil | India VII | Mauritania I | North Korea | Annotation |
| vivax02 | 14,100 | 18,100 | 4,000 | Δ | - | - | - | - | - | - | - | - | - | - | - | 5 | pseudogene |
| vivax06 | 71,800 | 74,000 | 2,200 | Δ | - | 116 | - | - | 4 | - | - | - | - | - | - | - | Phist protein |
| vivax09 | 1,536,000 | 1,537,600 | 1,600 | Δ | - | - | - | - | - | - | - | - | - | - | - | 82 | none |
| vivax14 | 780,100 | 781,500 | 1,400 | Δ | - | - | - | - | - | - | - | - | - | - | - | 20 | none |
| vivax14 | 3,061,600 | 3,069,300 | 7,700 | Δ | - | - | 7 | 81 | - | 52 | - | 62 | 15 | 27 | 18 | - | RBP2L |
| vivax06 | 382,600 | 390,700 | 8,100 | 2x | - | - | - | - | - | - | 21 | 2 | - | - | 3 | - | Duffy binding receptor |
The table shows for each sample the number of read pairs in unusual configuration indicating putative DNA sequence rearrangements. Dashes (-) indicate that no read pairs supported a sequence rearrangement at this location. See also Table S2.
Upstream chromosomal coordinate of the sequence rearrangement based on the Sal I reference sequence.
Downstream chromosomal coordinate of the sequence rearrangement based on the Sal I reference sequence.
Nucleotide length of the sequence rearrangement.
Δ = deletion; 2x = duplication.
none = no annotated gene.
Figure 1Duplication of the Duffy binding protein gene.
The top panel schematically shows the duplicated region and resulting read mapping on the Sal I reference genome. The bottom panels show, for M15 (Madagascar) and C08 (Cambodia), the number of read pairs per 100 bp non-overlapping bins (y-axis) that mapped head-to-head within the expected distance from each other (in blue) and read pairs that mapped tail-to-tail (in red). The x-axis corresponds to chromosome 6 between nucleotide positions 380,000 and 395,000. Note the elevated read coverage and presence of tail-to-tail read pairs in the M15 samples that are indicative of the PvDBP gene duplication and that are absent from the C08 sample (not duplicated).
Figure 2PvDBP gene duplication PCR diagnostic assay.
Panel A: Diagram of the PvDBP duplication and orientation of PCR primers to amplify control upstream (AF+AR; F = forward, R = reverse) and control downstream (BF+BR) fragments. Only when the sequence is duplicated will BF+AR primers amplify a PCR product. Panel B: Agarose gel following PCR amplification using AF+AR (Control) and BF+AR (Duplication) primers. Control products were obtained from the Madagascar (M19) and Cambodia (C127) samples; (-) indicates no DNA amplification from negative control (water). Duplication products were observed in Malagasy but not in Cambodian samples analyzed by whole genome sequencing.
Single Nucleotide Polymorphisms in the PvDBP gene of the M15 sample.
| Nucleotide Position | 389210 | 388688 | 388604 | 388601 | 388109 | 388091 | 387951 | 387752 | 387399 | 387300 | 386389 | 386352 | 386190 | 385646 |
|
| L17S | A146E | T174I | G175E | D339G | R345H | W392R | I458K | Q576K | K609E | K912N | D925N | Y979H | P1052P |
|
| A/G | G/T | G/A | C/T | T/C | C/T | A/G | A/T | G/T | T/C | T/A | C/T | A/G | A/G |
|
| 104/77 | 2/169 | 9/122 | 1/127 | 1/178 | 12/167 | 8/212 | 5/169 | 3/172 | 2/185 | 15/158 | 12/146 | 15/151 | 170/18 |
|
| 57 | 1 | 7 | 1 | 1 | 7 | 4 | 3 | 2 | 1 | 9 | 8 | 9 | 90 |
The table shows each polymorphic position in the PvDBP gene (PVX_110810), its resulting amino acid and reads supporting each allele at each position. Position 389210 is the nucleotide/amino acid change in the signal peptide likely differentiating the two PvDBP copies.
The reference allele is the PVX_110810 sequence.
Figure 3Global distribution of the PvDBP duplication allele in non-traveler (NT) and traveler (T) sample sets.
Blood samples from NT (filled stars) and T (filled circles) show the locations where the PvDBP duplication was detected (green) and not detected (red). Three locations included samples from NT and individuals that were infected with P. vivax strains that carried the PvDBP duplication (Sudan, Madagascar and Cambodia). Details regarding sample sizes for all NT and T sample sets are provided in Table S1.